Can Hba1c Act as A Surrogate Marker for Cardiovascular Risk?
Keywords:
Diabetes, Dyslipidemia, HbA1c, AIPAbstract
Aim: Glycosylated hemoglobin is a used marker for long-term glycemic control. This investigation is an attempt to evaluate the diagnostic value of HbA(1c) in predicting cardiovascular risk
Materials and methods:The study was conducted in V.S general hospital. 278 subjectsduringMay 2012 to October 2012, were included in the study. Details regarding to age, gender, duration of diabetes, were taken. Venous blood samples were collected and analyzed for glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), Total Cholesterol, Triglycerides, HDL-C and LDL-C and AIP.
Results:The total cholesterol and LDL cholesterol were significantly higher in females as compared to male diabetics. TG levels and AIP ratio were raised in the subjects <55 years compared to those >55 years. In cases with duration of diabetes > 6 years HbA1c, total cholesterol, TG,LDL cholesterol and AIP ratio were elevated but only total cholesterol and LDL cholesterol werestatistically significant. All the lipid parameters except HDL cholesterol were higher in subjects with HbA1c >7 % as compared to the group with HbA1c < 7%.
Conclusion: The findings indicate that HbA1c can provideauxiliary information about theextent of circulating lipids and AIP, and can thus be used as a predictor of cardiovascular risk in diabetics.
References
Global Prevalence of DiabetesEstimates for the year 2000 and projections for 2030. Available atwww.who.int/diabetes/ facts/en/diabcare0504.pdfAccessed on 23 nov 2013
Ronald K, Hyperglycemia and Microvascular and Macrovascular Disease in Diabetes, Diabetes Care,18(2), 1995, 258-268.
Irene M S,Amanda I A,Andrew W N, David R M, Susan EM etal,Association of glycaemiawith macrovascular and microvascularcomplications of type 2 diabetes (UKPDS 35): prospective observational study,BMJ ,321,2000,405–412.
Kreisberg RA, Diabetic dyslipidemia, Am J Cardiol, 82(12A),1998, 67U-73U.
Dobiásová M,AIP--atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice,VnitrLek, 52(1), 2006, 64-71.
Elizabeth S, Josef CSH, Golden,, Frederick L, Brancati,et al,Glycemic Control and Coronary Heart Disease Risk in Persons Withand Without Diabetes.The Atherosclerosis Risk in Communities Study, Arch Intern Med, 165, 2005, 1910-1916
Elizabeth S,Spyridon M, Gail B, Tejal R ,Frederick L. Brancati, NR., Sherita HG,Meta-Analysis: Glycosylated Hemoglobin andCardiovascular Disease in Diabetes Mellitus, Ann Intern Med 141(6), 2004, 421-431.
WoodwardA, WallymahmedM, Wilding J ,Gill G, Improvedglycemiccontrol:anunintended benefit of a nurse -led cardiovascular risk reduction clinic. Diabet Med, 22, 2005, 1272–1274.
Nakamura K, Yamagishi SI, Adachi H, Kurita -Nakamura Y, Matsui T, Yoshida T, Sato A, Imaizumi T,Elevation of soluble formof receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease,Diabetes Metab ResRev 23(5), 2007, 368–371.
Position statement, Standards of Medical Care in Diabetes-2012, Diabetes Care, 35 (1), 2012, S11-S63.
Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) http://www.nhlbi.nih.gov/guidelines/ cholesterol/atp3full.pdf.
Dobiasova M,Frohlich J, The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL), ClinBiochem, 34(7), 2001, 583-588.
Bloor W R., The lipoids of the blood in diabetes. J. Biol.Chem. 26, 1916, 417-30.
Suhuan L, Franck MJ,Minireview: EstrogenicProtection ofβ-Cell Failure in Metabolic Diseases,Endocrinology, 151, 2010,859–864
Mayumi, O., Seiji, N., Yoko, I., Eiko, Y. et al, . Effects of Post-menopausal Hormone Replacement Therapy on HbA1c levels,Diabetes care, 26, 2003, 1088-1092
TremollieresFA, Pouilles JM, Cauneille C, Ribot C,Coronary heart disease risk factors and menopause: a study in 1684 French women, Atherosclerosis 142(2), 1999, 415-23
No authors listed] (1997) U.K. Prospective Diabetes Study 27,Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 20, 1683–1687
H.O. Otamere, C.P Aloamaka,PO.Okokhere , W.A. Adisa,Lipid Profile in Diabetes Mellitus;What Impact Has Age andDuration,. Br. J. Pharmacol. Toxicol, 2(3), 2011, 135-137,
Amy SS,Lawrence M D, Thomas R K, Zhiqian G, Philip R K, Stephen R D, Elaine MU,Influence of Duration of Diabetes, Glycemic Control, and Traditional Cardiovascular Risk Factors on EarlyAtherosclerotic Vascular Changes in Adolescents andYoung Adults with Type 2 Diabetes Mellitus. J ClinEndocrinolMetab 94, 2009, 3740–3745.
Ronald K, Barbara EK, Scot E M,Relation of Glycemic Control to DiabeticMicrovascular Complications in Diabetes Mellitus,AnnIntern Med, 124(1_Part_2), 1996, 90-96.
David MN, The Pathophysiology of Diabetic Complications: How Much Does the Glucose Hypothesis Explain? Ann Intern Med,124(1_Part_2), 1996, 86-89.
Haseeb AK,Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2diabetic patients Act aDiabetol,Springer-Verlag 2007.
Ladeia AM, Adan L, Couto-Silva AC, Hiltner A, Guimaraes AC Lipid profile correlates with glycemic control in young patientswith type 1 diabetes mellitus. PrevCardiol, 9, 2006, 82–88
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The authors retain the copyright of their article, with first publication rights granted to Medsci Publications.
